Wezlana is a biologic therapy indicated for the maintenance treatment of moderate to severe asthma in individuals aged 12 years and above. It targets specific inflammatory markers in the immune system, helping to decrease airway inflammation and prevent exacerbations. Wezlana is typically administered via injection and is used alongside standard asthma controller medications such as inhaled corticosteroids and bronchodilators. By reducing the frequency of asthma attacks and improving overall respiratory function, Wezlana offers long-term support for patients whose symptoms are not adequately controlled with traditional therapies.